XGN - Exagen receives DoJ subpoena related to alleged federal healthcare regulations violations
Exagen (NASDAQ:XGN) disclosed in its annual report that it has received a subpoena from the U.S. Department of Justice "requesting documents related to its investigation of potential federal regulatory healthcare offenses." The company said that it is cooperating fully and is working to provide the information to DoJ. However, Exagen (XGN) also noted that responding to the subpoena and dealing with a government investigation "diverts the attention of our management team and diverts resources from our core business." Check out Exagen's (XGN) recent Q4 2021 results.
For further details see:
Exagen receives DoJ subpoena related to alleged federal healthcare regulations violations